Pury Peptide

普瑞巴肽

Report date: 2024/05/22 15:21:19
NME

Base Information

Drug NamePury Peptide
Drug Alias NameMT-1001
ClassificationSmall molecules > Synthetic peptide
Mechanisms of ActionIntegrin alpha-IIb/beta-3 antagonists
TargetsIntegrin alpha-IIb/beta-3
Therapy Area/IndicationsAcute Coronary Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShaanxi Micot Pharmaceutical Technology Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesShaanxi Micot Pharmaceutical Technology Co Ltd
Inactive CompaniesN/A
Active IndicationsAcute Coronary Syndrome
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A